PL2327763T3 - Generowanie komórek T specyficznych względem antygenu - Google Patents

Generowanie komórek T specyficznych względem antygenu

Info

Publication number
PL2327763T3
PL2327763T3 PL10179257T PL10179257T PL2327763T3 PL 2327763 T3 PL2327763 T3 PL 2327763T3 PL 10179257 T PL10179257 T PL 10179257T PL 10179257 T PL10179257 T PL 10179257T PL 2327763 T3 PL2327763 T3 PL 2327763T3
Authority
PL
Poland
Prior art keywords
cells
antigen specific
generation
directed
specific
Prior art date
Application number
PL10179257T
Other languages
English (en)
Inventor
Dolores Schendel
Susanne Wilde
Thomas Blankenstein
Original Assignee
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh, Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) filed Critical Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Publication of PL2327763T3 publication Critical patent/PL2327763T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL10179257T 2005-08-05 2006-08-04 Generowanie komórek T specyficznych względem antygenu PL2327763T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05017128 2005-08-05
EP06007539 2006-04-10
EP10179257.0A EP2327763B1 (en) 2005-08-05 2006-08-04 Generation of antigen specific T cells
EP06776623A EP1910521B1 (en) 2005-08-05 2006-08-04 Generation of allorestricted antigen specific t cells

Publications (1)

Publication Number Publication Date
PL2327763T3 true PL2327763T3 (pl) 2018-08-31

Family

ID=37598202

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10179257T PL2327763T3 (pl) 2005-08-05 2006-08-04 Generowanie komórek T specyficznych względem antygenu

Country Status (11)

Country Link
US (2) US8486694B2 (pl)
EP (3) EP2327763B1 (pl)
JP (3) JP5079697B2 (pl)
AT (1) ATE484578T1 (pl)
DE (1) DE602006017556D1 (pl)
DK (2) DK1910521T3 (pl)
ES (2) ES2842878T3 (pl)
HU (1) HUE038833T2 (pl)
PL (1) PL2327763T3 (pl)
PT (1) PT2327763T (pl)
WO (1) WO2007017201A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
PL2327763T3 (pl) * 2005-08-05 2018-08-31 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generowanie komórek T specyficznych względem antygenu
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
EP2393833A1 (en) * 2009-02-09 2011-12-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
BR112013006718B1 (pt) * 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
JP6389166B2 (ja) 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
CA2873608A1 (en) * 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
JP2016539117A (ja) * 2013-11-22 2016-12-15 セレクティスＣｅｌｌｅｃｔｉｓ 平均化された効力を持つ同種異系ｔ細胞のバッチを生成するための方法
CN106659913A (zh) * 2014-03-20 2017-05-10 H.李莫菲特癌症中心研究院 用于过继细胞疗法的肿瘤浸润淋巴细胞
AU2015247727A1 (en) * 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
CA2964785A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
WO2016146618A1 (en) * 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
US10858760B2 (en) 2015-06-01 2020-12-08 Medigene Immunotherapies Gmbh T cell receptor library
EA201792661A1 (ru) 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх Способ получения антител против т-клеточного рецептора
US20170119820A1 (en) 2015-07-31 2017-05-04 Regents Of The University Of Minnesota Modified cells and methods of therapy
DK3350213T3 (da) * 2015-09-15 2021-06-21 Us Health T-cellereceptorer som genkender hla-cw8-begrænset muteret kras
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
ES2863733T3 (es) 2015-12-23 2021-10-11 Medigene Immunotherapies Gmbh Generación novedosa de TCR específicos de antígeno
JP7019578B2 (ja) * 2015-12-30 2022-02-15 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EA201990591A1 (ru) * 2016-09-23 2019-08-30 Фред Хатчинсон Кэнсер Рисерч Сентер Tcr, специфичные к минорному антигену гистосовместимости (h) ha-1, и их применения
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
KR102490850B1 (ko) 2018-02-26 2023-01-26 메디진 이뮤노테라피스 게엠바하 Nyeso t 세포 수용체
EP3849569A4 (en) * 2018-09-10 2022-06-08 Torque Therapeutics, Inc. ANTIGEN-SPECIFIC T LYMPHOCYTES AND METHODS OF MAKING AND USING THEM
BR112021005596A2 (pt) * 2018-09-27 2021-06-29 Genocea Biosciences Inc. métodos de tratamento
CA3122843A1 (en) * 2018-12-12 2020-06-18 The Brigham And Women's Hospital, Inc. Compositions and methods for immunosuppression
TW202102530A (zh) 2019-04-04 2021-01-16 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
JP6878544B2 (ja) * 2019-10-02 2021-05-26 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP7340144B2 (ja) * 2019-10-02 2023-09-07 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
EP4126962A1 (en) 2020-04-01 2023-02-08 Medigene Immunotherapies GmbH Cd3-fusion protein and uses thereof
WO2022038115A1 (en) 2020-08-18 2022-02-24 Medigene Immunotherapies Gmbh ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY
EP4217380A1 (en) 2020-09-24 2023-08-02 Medigene Immunotherapies GmbH Prame specific t-cell receptors and uses thereof
WO2023175070A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library
WO2023175069A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library for pramevld tcrs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4767371B2 (ja) 1996-01-17 2011-09-07 インペリアル・イノベイションズ・リミテッド 細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
DE50207025D1 (de) * 2002-08-23 2006-07-06 Deutsches Rheuma Forschungszen Verfahren zum Nachweis und zur Isolierung von T-Lymphozyten, die ein definiertes Antigen erkennen
PL2327763T3 (pl) * 2005-08-05 2018-08-31 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generowanie komórek T specyficznych względem antygenu

Also Published As

Publication number Publication date
EP1910521A1 (en) 2008-04-16
WO2007017201A1 (en) 2007-02-15
JP2016135127A (ja) 2016-07-28
PT2327763T (pt) 2018-05-11
EP2327763B1 (en) 2018-03-14
ES2672895T3 (es) 2018-06-18
EP3369812B1 (en) 2020-10-07
EP1910521B1 (en) 2010-10-13
DK1910521T3 (da) 2011-02-07
US8486694B2 (en) 2013-07-16
HUE038833T2 (hu) 2018-11-28
ES2842878T3 (es) 2021-07-15
JP5079697B2 (ja) 2012-11-21
DE602006017556D1 (de) 2010-11-25
ATE484578T1 (de) 2010-10-15
EP2327763A1 (en) 2011-06-01
JP2012213402A (ja) 2012-11-08
DK2327763T3 (en) 2018-05-22
US20100189728A1 (en) 2010-07-29
EP3369812A1 (en) 2018-09-05
JP2009502185A (ja) 2009-01-29
US20140141026A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
HUE038833T2 (hu) Antigénspecifikus T-sejtek létrehozása
Wolf et al. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy
Schatton et al. ABCB5 identifies immunoregulatory dermal cells
Jenq et al. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
Mandal et al. Polymer-based synthetic dendritic cells for tailoring robust and multifunctional T cell responses
CY1121857T1 (el) Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα
WO2006050138A3 (en) Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
WO2003046141A3 (en) Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
WO2005004592A8 (en) Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2004003142A3 (en) Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
MY147516A (en) Compositions and method of vascular injury repair cross-reference to related applications
BR0211491A (pt) Geração de células dendrìticas totalmente madura e estáveis de produtos de leucafereses para aplicações clìnicas
ATE544849T1 (de) Aktivierte dendritische zellen, therapieverfahren unter verwendung der dendritischen zellen sowie verfahren zur kultivierung von gamma-delta-t- zellen
ATE498633T1 (de) Materialien und verfahren zur stimulierung des immunsystems
ATE324030T1 (de) Brassica-transformation durch teilchenbeschuss
Moon et al. Use of epigenetic modification to induce FOXP3 expression in naïve T cells
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
NO20060561L (no) Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
AP2368A (en) Novel expression vectors and uses thereof.
WO2006101891A3 (en) Antigens targeted by pathogenic t cells in type 1 diabetes and uses thereof